Benzinga | Aug 20, 2020 06:20AM EDT

Stifel Downgrades Momenta Pharmaceuticals to Hold, Raises Price Target to $52.5

Stifel analyst Derek Archila downgrades Momenta Pharmaceuticals (NASDAQ:MNTA) from Buy to Hold and raises the price target from $47 to $52.5.